Schmiegel W H, Eberl W, Kreiker C, Kalthoff H, Bützow G H, Jessen K, Klapdor R, Soehendra N, Wargenau M, Classen M
Hepatogastroenterology. 1985 Jun;32(3):141-5.
With respect to their diagnostic utility CA 19-9, CEA, AFP and POA were determined in pancreatic secretions and serum of patients suffering from pancreatic cancer (n = 76/55) or chronic pancreatitis (n = 79/45) and of controls (n = 81/42), respectively. While the determination of AFP and POA both in pancreatic secretions and serum does not permit a differential diagnosis, serum CEA (greater than 10 ng/ml) and CA 19-9 (greater than 50 U/ml) levels were indicative of pancreatic cancer in 30% and 83%, respectively, with a rate of false positive results of 5% and 8.5% confined to the chronic pancreatitis patients. A combination of tumor marker analyses, that is, serum CA 19-9 (greater than 50 U/ml) and pancreatic secretion CEA (greater than 70 ng/ml), proved to be positive in 92.9% of tumor patients with a maximum of 10.5% false positives. Likewise, values of serum CA 19-9 (greater than 50 U/ml) and serum CEA (greater than 10 ng/ml) were found in 85.8% of the pancreatic cancer patients with only 8.8% false positives, which were confined to the chronic pancreatitis patients. These results indicate the superiority of multiparametric tumor marker analyses for the diagnosis of pancreatic cancer, especially when including new monoclonal antibody defined tumor markers.
分别对患有胰腺癌（n = 76/55）、慢性胰腺炎（n = 79/45）的患者以及对照组（n = 81/42）的胰腺分泌物和血清进行了CA 19-9、癌胚抗原（CEA）、甲胎蛋白（AFP）和胰癌胚抗原（POA）的检测，以评估它们的诊断效用。虽然对胰腺分泌物和血清中的AFP和POA进行检测无法实现鉴别诊断，但血清CEA（大于10 ng/ml）和CA 19-9（大于50 U/ml）水平分别在30%和83%的情况下可提示胰腺癌，慢性胰腺炎患者的假阳性率分别为5%和8.5%。肿瘤标志物分析组合，即血清CA 19-9（大于50 U/ml）和胰腺分泌物CEA（大于70 ng/ml），在92.9%的肿瘤患者中呈阳性，最高假阳性率为10.5%。同样，85.8%的胰腺癌患者血清CA 19-9（大于50 U/ml）和血清CEA（大于10 ng/ml）呈阳性，仅8.8%为假阳性，且仅限于慢性胰腺炎患者。这些结果表明多参数肿瘤标志物分析在胰腺癌诊断方面具有优势，尤其是在纳入新的单克隆抗体定义的肿瘤标志物时。
